

ASX RELEASE**15 June 2021****ASX: NVU**

Nanoshield antiviral protection drives record sales

Highlights:

- **Nanoveu on track for a record-breaking quarter of sales¹ driven by international uptake of Nanoshield antiviral film**
- **Unaudited sales for current quarter equalling previous best result², with >2 weeks remaining until quarter-end**
- **Sales increasing to flagship customer Nestlé Professional as regional divisions seek greater access to Nanoshield**
- **Exclusive distribution partners proceeding through onboarding process and building greater market awareness**

Nanoveu Limited (ASX: NVU) ("Nanoveu" or the "Company") is pleased to announce the Company is on track to deliver record revenue for the quarter ending 30th June 2021 resulting from increased sales of the Nanoshield antiviral protection technology.

Increasing interest in Nanoshield, which is available as a commercial roll of film or in a number of pre-cut units such as tape and push-pads, has seen unaudited sales for the quarter equal its previous best result (December Quarter 2020: A\$180,000). With more than two-weeks remaining in the June Quarter, the Company is set to deliver its highest ever quarterly sales orders.

Commenting on the record-breaking period, Nanoveu Executive Chairman and CEO Alfred Chong said:

"Nanoveu continues to see interest emerge across the globe for our antiviral protection technologies. The increasing sales figures buoy our expectation that Nanoshield will become increasingly relevant for a wide range of customers seeking greater protection and peace-of-mind when operating high-touch surfaces."

"It is incredibly pleasing to deliver another record period of growth for the Company. I look forward to providing an update in our upcoming quarterly report to further detail our increasing pipeline of opportunities."

Sales to date have been boosted by an increasingly diversified order-base from flagship customer Nestlé Professional. A number of regional divisions have purchased Nanoshield protection, with shipments made to the likes of Nestlé Professional in Greece, Australia and Austria.

In addition, the Company has seen a number of its exclusive distribution partners advance through Nanoveu's distributor onboarding process, whereby partners undertake a number of

¹ All sales and revenue referenced in the announcement are unaudited

² See ASX announcement of 28 January 2021

steps prior to establishing full-scale commercial operations³. As distributor partners progress through the process, the Company anticipates expanded opportunities to drive additional sales.

Nanoveu intends to continue its strategy of establishing distribution partnerships in major markets, which enhance sales capabilities without having to deploy significant amounts of capital building in-house distribution.

In addition, Nanoveu continues to promote direct-to-consumer sales through its online sales portal (<https://www.nanoshield.co/shop>) and is pursuing additional B2B opportunities with a number of prospective organisations.

Nanoveu's antiviral technology has been independently demonstrated to be a highly effective agent for the eradication of viruses. The technology has been proven to eliminate 99.99%⁴ of OC43, a viral strain affecting humans that is also a surrogate for COVID-19, in 30 minutes. The antiviral protection has also been validated against other bacteria and viruses including e.Coli, Influenza A (subtype H3N2), and coronavirus MHV-A59⁵. Additionally, testing simulating 12 months outside weather conditions has found Nanoveu's products retain their effectiveness against MS2 Bacteriophage, a single-strand RNA virus⁶.

- Ends -

This announcement has been authorised for release by Nanoveu's Executive Chairman and CEO.

For further information, please contact:

Alfred Chong
Executive Chairman and CEO

t: +65 6557 0155
e: info@nanoveu.com

For media / investor enquiries, please contact:

David Tasker / Alex Baker
Chapter One Advisors

t: + 61 433 112 936 / +61 432 801 745
e: dtasker@chapteroneadvisors.com.au

About Nanoveu:

Nanoveu is a technology company developing a range of products for mobile phones and other digital displays. The Company's wholly-owned, flagship product is its Nanoshield antiviral protection which is available in a variety of mobile phone screen covers, mobile phone cases and as a commercial film capable of being applied to a number of surfaces. The product is a clear plastic containing a layer of charged copper nanoparticles which have antiviral and antimicrobial properties. The product is commercially available and sold in a number of countries via Nanoveu's channel partners. Nanoveu also produces EyeFly3D™, which converts 2D digital displays into 3D

³ See ASX announcement of 27 April 2021

⁴ See ASX announcements of 5 and 25 May 2020

⁵ See ASX announcement of 15 April 2020

⁶ See ASX announcement of 18 February 2021



without the need for 3D glasses and is currently available for Apple iPhones and Google Pixel 3 phones.

In addition, the Company is also developing the following products:

- Customskins: vending machines capable of precisely applying screen covers to mobile phones in just over a minute and with an alignment accuracy of 150 microns;
- EyeFyx: a vision correction solution under development using hardware and software to manipulate screen output; and
- Anti-reflective coating technology capable of being applied to mobile phones, tablets, automotive displays and other digital displays.